Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 42872-73-1 | MDL No. : | MFCD00158968 |
Formula : | C8H6BrN | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | JWCMJJIZYDCGTE-UHFFFAOYSA-N |
M.W : | 196.04 | Pubchem ID : | 820802 |
Synonyms : |
|
Num. heavy atoms : | 10 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.12 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 1.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 43.82 |
TPSA : | 23.79 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.58 cm/s |
Log Po/w (iLOGP) : | 2.12 |
Log Po/w (XLOGP3) : | 2.7 |
Log Po/w (WLOGP) : | 2.63 |
Log Po/w (MLOGP) : | 2.52 |
Log Po/w (SILICOS-IT) : | 2.94 |
Consensus Log Po/w : | 2.58 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 2.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -3.2 |
Solubility : | 0.124 mg/ml ; 0.00063 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.85 |
Solubility : | 0.275 mg/ml ; 0.0014 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.73 |
Solubility : | 0.0368 mg/ml ; 0.000188 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.76 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
98% | With phosphorus pentoxide In chloroform for 12 h; Reflux | Example 10 2-Bromo-4-methylbenzonitrile To a suspension of 2-bromo-4-methylbenzamide (14.8 g, 69.1 mmol) in CHCl3 was added phosphorous pentoxide (24.5 g, 172.8 mmol) and the mixture keep refluxing for 12 h. The reaction was allowed to cool to room temperature, and put into the ice water under the condition of stirring. The organic layer was separated and the aqueous layer was extracted with CHCl3 (150 mL*2). The combined organic phase was washed with brine, and dried over Na2SO4. Evaporation of the solvent afforded the title compound, 2-bromo-4-methylbenzonitrile (13.3 g, 98percent). 1H NMR (400 MHz, CDCl3) δ 2.41 (s, 3H), 7.20 (d, J=8.0 Hz, 1H), 7.51-7.54 (m, 2H). |
98% | With phosphorus pentoxide In chloroform for 12 h; Reflux | Example 10 2-Bromo-4-methylbenzonitrile To a suspension of 2-bromo-4-methylbenzamide (14.8 g, 69.1 mmol) in CHCl3 was added phosphorous pentoxide (24.5 g, 172.8 mmol) and the mixture keep refluxing for 12 h. The reaction was allowed to cool to room temperature, and put into the ice water under the condition of stirring. The organic layer was separated and the aqueous layer was extracted with CHCl3 (150 mL*2). The combined organic phase was washed with brine, and dried over Na2SO4. Evaporation of the solvent afforded the title compound, 2-bromo-4-methylbenzonitrile (13.3 g, 98percent). 1H NMR (400 MHz, CDCl3) δ 2.41 (s, 3H), 7.20 (d, J=8.0 Hz, 1H), 7.51-7.54 (m, 2H). |
98% | With phosphorus pentoxide In chloroform for 12 h; Reflux | Example 13 2-Bromo-4-methylbenzonitrile To a suspension of 2-bromo-4-methylbenzamide (14.8 g, 69.1 mmol) in CHCl3 was added phosphorous pentoxide (24.5 g, 172.8 mmol) and the mixture keep refluxing for 12 h. The reaction was allowed to cool to room temperature, and put into the ice water under the condition of stirring. The organic layer was separated and the aqueous layer was extracted with CHCl3 (150 mL*2). The combined organic phase was washed with brine, and dried over Na2SO4. Evaporation of the solvent afforded the title compound, 2-bromo-4-methylbenzonitrile (13.3 g, 98percent). 1H NMR (400 MHz, CDCl3): δ 2.41 (s, 3H), 7.20 (d, J=8.0 Hz, 1H), 7.51-7.54 (m, 2H). |
98% | With phosphorus pentoxide In chloroform for 12 h; Reflux | Example 10 2-Bromo-4-methylbenzonitrileTo a suspension of 2-bromo-4-methylbenzamide (14.8 g, 69.1 mmol) in CHCI3 was added phosphorous pentoxide (24.5 g, 172.8 mmol) and the mixture keep refluxing for 12 h. The reaction was allowed to cool to room temperature, and put into the ice water under the condition of stirring.The organic layer was separated and the aqueous layer was extracted with CHCI3 (150 mL x 2).The combined organic phase was washed with brine, and dried over Na2SOzI. Evaporation of the solvent afforded the title compound, 2-bromo-4-methylbenzonitrile (13.3 g, 98percent). 1H NMR (400MHz, CDCl3) δ 2.41 (s, 3 H), 7.20 (d, J=8.0 Hz, 1 H), 7.51-7.54 (m, 2 H). |
84% | Stage #1: for 4 h; Heating / reflux Stage #2: at 0℃; for 0.166667 h; |
2-Bromo-4-methylbenzonitriIe (TJA02020) C8H6BrN MW 196.04. Phosphorus oxychloride (22.6 mL, 243 mmol), TJA02017 (4.00 g, 18.7 mmol) and sodium chloride (2.40 g, 41.1 mmol) were loaded to a 100 mL r.b. flask and set to reflux with stirring for 4 h. The mixture was allowed to cool and excess phosphorus oxychloride was removed via a rotary evaporator. The resultant brown residues were poured into iced water with stirring and left for 10 min. A brown ppt. had formed and was collected via filtration, washed thoroughly with distilled H2O and dried under vacuum at 70 °C.Recrystallisation (hexane) yielded the title compound as a white crystalline solid (3.07 g,84 percent), mp 49.9-51.9 0C;1H NMR (270 MHz, CDCl3) δ 2.40 (3H, s, ArH), 7.18-7.22 (IH, d, J= 8.6 Hz, ArH) and7.49-7.54 (2H, m, AJγH);13C NMR (67.9 MHz, CDCl3) δ 21.7 (CH3), 112.8 (C), 117.5 (C), 125.2 (C), 128.6 (CH),133.8 (CH), 134.1 (CH) and 145.5 (C); HPLC (70 percent CH3CN in H2O) tτ =4.917 (99.75 percent);LCMS (APCI)5 m/z 198.07 (81BrM+ + H, 100 percent), 196.07 (79BrM+ + H, 98 percent). |